The present invention relates to pyrazol-isoxazole compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents. Conditions which may be treated with the compounds include: psoriasis, psoriatric arthritis, autoimmune thyroiditis, Grave&rsquo；s disease, rheumatoid arthritis, vitiligo, Crohn&rsquo；s disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, diabetes type I, multiple sclerosis, celiac disease, systemic lupus erythematosus, uveitis, Behcet disease, atopic dermatitis, Lichen planus, Sjogren&rsquo；s syndrome, spinal disc herniation, acne, Graft-versus-Host-Reaction, Host -versus-Graft-Reaction and osteoarthritis. Compounds of the disclosure include: 2-(3-(2-chloro-6-fluorophenyl)-5-(1-(3-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)-5-( trifluoromethyl)-1,3,4-oxadiazole, 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H -pyrazol-4-yl)-4-( 4-methylthiazol-2-yl)isoxazole, 2-(3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazol-4-yl)-5-methyl-1,3,4-oxadiazole, 3-(2-chloro-6-fluorophenyl)-5-(1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4-(furan-2-yl)isoxazole, and 3-(2-chloro-6-fluorophenyl)-5-(I-(3-chlorophenyl)-5-(trifluoromethyl)-IH-pyrazol-4-yl)-4-(1,3,4-thiadiazol-2-yl)isoxazole.
